Provided by Tiger Trade Technology Pte. Ltd.

Quantum Biopharma Ltd.

9.70
+1.1313.19%
Post-market: 9.38-0.3200-3.30%18:14 EST
Volume:111.35K
Turnover:1.01M
Market Cap:37.02M
PE:-0.96
High:10.02
Open:8.20
Low:8.01
Close:8.57
52wk High:38.25
52wk Low:2.70
Shares:3.82M
Float Shares:3.55M
Volume Ratio:0.24
T/O Rate:3.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0975
EPS(LYR):-12.4923
ROE:-251.26%
ROA:-72.22%
PB:4.28
PE(LYR):-0.78

Loading ...

Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC

GlobeNewswire
·
Dec 01

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

GlobeNewswire
·
Nov 28

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

GlobeNewswire
·
Nov 26

Quantum Biopharma Ltd expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Nov 08

Quantum BioPharma's digital asset portfolio has achieved a $572,000 return since the beginning of the year

Blockbeats
·
Nov 07

Press Release: Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Dow Jones
·
Nov 07

Quantum BioPharma Ltd. Provides Corporate Update

GlobeNewswire
·
Nov 01

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

GlobeNewswire
·
Oct 23

Press Release: Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Dow Jones
·
Oct 20

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

GlobeNewswire
·
Oct 14

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

GlobeNewswire
·
Oct 08

Press Release: Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Dow Jones
·
Oct 03

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

GlobeNewswire
·
Oct 02

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

GlobeNewswire
·
Oct 01

Press Release: Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Dow Jones
·
Sep 29

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

GlobeNewswire
·
Sep 24

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

GlobeNewswire
·
Sep 18

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

GlobeNewswire
·
Sep 12

Quantum BioPharma Announces Corporate Updates

GlobeNewswire
·
Aug 21

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

GlobeNewswire
·
Aug 11